5 rezultātiem
This study aims to evaluate:
1. the first line H. pylori eradication rate of high dose dual therapy with 14 days rabeprazole 20 mg qid, plus amoxicillin 500 mg qid (HDDT group) comparing to the clarithromycin-based triple therapy with 14 days clarithromycin 500 mg bid, amoxicillin 1000mg bid , and
Introduction:
H. pylori has been declared and ratified as carcinogen I by the World health organization (WHO) International agency for research on cancer (IARC). Globally first line therapy eradication treatment recommended for H. pylori, combines a proton-pump inhibitor (PPI) with two antibiotics
Purpose of the research:
- To determine the onset of effective analgesia (Numerical Rating Scale (NRS) for pain = 1/10 in minutes with the modified CSE and DPE techniques, which is our primary outcome.
- To assess block quality (time to T10 sensory block, motor block, asymmetric block, inadequate
The aim of our prospective study is to investigate the rate of H pylori resistant strains to antibiotic treatment including Amoxicillin, Clarithromycin, Metronidazole, Tetracycline and Quinolones in pediatric population in Ha-Emek medical center, Afula. The second aim was to determine if in vitro
Some clinical parameters were evaluated according to the following: primary outcome (severity of diarrhea), and secondary outcome including body weight change, appetite and daily intake, bloating or abdominal distension, abdominal pain or colic, constipation, fever, and vomiting were also